Abstract:Purpose To comparatively evaluate the prognostic or predictive value of ribonucleotide reductase M1 (RRM1) and excision repair cross-complementation 1 (ERCC1) gene expression in peripheral blood versus tumor tissue from patients with advanced non-small cell lung cancer (NSCLC) treated by gemcitabine/platinum chemotherapy. Methods A total of 49 patients with advanced NSCLC receiving gemcitabine plus carboplatin chemotherapy were studied. RRM1 and ERCC1 mRNA levels in the peripheral blood and tumor tissue were determined by real-time fluorescent quantitative PCR. The relationships between gene expression and clinical and pathological factors, response to chemotherapy as well as prognosis, were evaluated. Results RRM1 expression in peripheral blood and tumor tissue, but not ERCC1 expression, was found to be positively correlated ( r = 0.332, 0.258; P = 0.020, 0.073; respectively). RRM1 and ERCC1 expression levels were nearly synchronous in both peripheral blood ( r = 0.351; P = 0.013) and tumor tissue ( r = 0.634; P < 0.001). Neither was correlated with clinical and pathological factors. Patients with low RRM1 expression in peripheral blood or low RRM1 or ERCC1 expression in tumor tissue experienced better response to chemotherapy (50.0 vs. 16.0%, 50.0 vs. 16.0%, and 54.2 vs. 12.0%; P = 0.012, 0.012, and 0.003; respectively), longer median survival (18.5 vs. 13.0 months, 18.5 vs. 12.0 months, and 19.8 vs. 12.5 months; P = 0.043, 0.014 and 0.007; respectively), and longer progression-free survival (6.0 vs. 4.0 months, 7.8 vs. 3.9 months, and 5.8 vs. 3.8 months; P = 0.044, 0.016, and 0.008; respectively). Cox multivariate regression analysis showed that ERCC1 expression in tumor tissue was independent indicator for overall survival. Conclusions Advanced NSCLC patients with low RRM1 mRNA expression both in peripheral blood and in tumor tissue could benefit from gemcitabine/carboplatin chemotherapy. ERCC1 mRNA expression in tumor tissue may be a predictive and prognostic indicator in advanced NSCLC patients receiving gemcitabine/carboplatin chemotherapy.

Relation of HENT1 Mrna Expression with the Prognosis of Non-Small Cell Lung Cancer Patients Received Gemcitabine-Based Chemotherapy

Human Equilibrative Nucleoside Transporter 1: Novel Biomarker and Prognostic Indicator for Patients with Gemcitabine-Treated Pancreatic Cancer

Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: a meta-analysis.

RRM1 Gene Expression in Peripheral Blood is Predictive of Shorter Survival in Chinese Patients with Advanced Non-Small-cell Lung Cancer Treated by Gemcitabine and Platinum

Effect of RRM1 and BRCA1 Expressions on Efficiency of Gemcitabine and Platinum in Patients with Advanced Non-Small Cell Lung Cancer

Relationships Between Expression of Glucose Transporter Protein-1 and Hypoxia Inducible Factor-1Α, Prognosis and 18F-FDG Uptake in Laryngeal and Hypopharyngeal Carcinomas

First-line Gemcitabine Plus Cisplatin in Nonsmall Cell Lung Cancer Patients.

Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial

"Open Sesame?": Biomarker Status of the Human Equilibrative Nucleoside Transporter-1 and Molecular Mechanisms Influencing its Expression and Activity in the Uptake and Cytotoxicity of Gemcitabine in Pancreatic Cancer

The Clinicopathological and Prognostic Implications of Tyrosine Phosphatase SHP2 and Ankyrin Hook1 Gene Expression in Non- Small Cell Lung Cancer Patients Treated with Gemcitabine Plus Platinum As First-Line Chemotherapy

RRM1 Mrna Expression Levels in Malignant Pleural and Peritoneal Effusions Are Associated with Chemosensitivity to Gemcitabine in Vitro

Expressions of the Genes Related to Chemotherapeutic Sensitivity in Non-Small Cell Lung Cancer and Their Correlation to Its Clinical Pathology

Human equilibrative nucleoside transporter-1 expression is a predictor in patients with resected pancreatic cancer treated with adjuvant S-1 chemotherapy

Low expression of equilibrative nucleoside transporter 1 is associated with poor prognosis in chemotherapy-naïve pT2 gallbladder adenocarcinoma patients

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression.

Genes Correlated with Gemcitabine Efficacy in Non-small Cell Lung Cancer

Rrm1 and Ercc1 Expression in Peripheral Blood Versus Tumor Tissue in Gemcitabine/Carboplatin-Treated Advanced Non-Small Cell Lung Cancer

Identification of lncRNA Signature of Tumor-Infiltrating T Lymphocytes With Potential Implications for Prognosis and Chemotherapy of Head and Neck Squamous Cell Carcinoma

Expression of RRM1 and ERCC1 Genes in Tumor Tissues and Peripheral Blood Lymphocytes of Advanced Non-Small Cell Lung Cancer

Long Non-Coding MELTF Antisense RNA 1 Promotes and Prognosis the Progression of Non-Small Cell Lung Cancer by Targeting Mir-1299

Relation of NM23-H1 and CD44v6 Expression to Patient's Prognosis in the Non-Small Cell Lung Cancer Without Lymph Node Metastasis